AIM
CPRX

Acrospire Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Acrospire Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,268
Closed -$20K – 323
2017
Q2 		$20K Sell
7,268
-2,500
-26% -$5.22K 0.02% 1516
2017
Q1 		$19K Buy
9,768
+868
+10% +$1.11K 0.02% 1650
2016
Q4 		$9K Buy
+8,900
New +$10.2K ﹤0.01% 1964

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

Acrospire Investment Management's CPRX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2017, closing a stake of 7,268 shares — an estimated $20K sold.

Acrospire Investment Management first reported a position in CPRX in Q4 2016 and held it in 3 quarters. The position peaked at $20K in Q2 2017. 80 funds tracked by Wall St. Rank hold CPRX as of Q3 2017.

  • Acrospire Investment Management reported no remaining Catalyst Pharmaceutical position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 7,268 Catalyst Pharmaceutical shares in Q3 2017, an estimated $20K.
  • Acrospire Investment Management first reported a position in Catalyst Pharmaceutical in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Catalyst Pharmaceutical position peaked at $20K in Q2 2017.
  • 80 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.